86 related articles for article (PubMed ID: 20939648)
1. A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients.
Sato Y; Yasui-Furukori N; Furukori H; Saito M; Nakagami T; Kaneko S
Exp Clin Psychopharmacol; 2010 Oct; 18(5):445-50. PubMed ID: 20939648
[TBL] [Abstract][Full Text] [Related]
2. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
[TBL] [Abstract][Full Text] [Related]
3. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
4. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
5. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
[TBL] [Abstract][Full Text] [Related]
7. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
Ader M; Garvey WT; Phillips LS; Nemeroff CB; Gharabawi G; Mahmoud R; Greenspan A; Berry SA; Musselman DL; Morein J; Zhu Y; Mao L; Bergman RN
J Psychiatr Res; 2008 Oct; 42(13):1076-85. PubMed ID: 18295798
[TBL] [Abstract][Full Text] [Related]
8. Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.
Filaković P; Laufer D; Radanović-Grgurić L; Koić O; Fijacko M; Durković M
Psychiatr Danub; 2005 Jun; 17(1-2):63-6. PubMed ID: 16395845
[TBL] [Abstract][Full Text] [Related]
9. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Melkersson K; Berinder K; Hulting AL
Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
[TBL] [Abstract][Full Text] [Related]
10. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
[TBL] [Abstract][Full Text] [Related]
11. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.
Smith RC; Lindenmayer JP; Bark N; Warner-Cohen J; Vaidhyanathaswamy S; Khandat A
Int J Neuropsychopharmacol; 2005 Jun; 8(2):183-94. PubMed ID: 15737248
[TBL] [Abstract][Full Text] [Related]
12. Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.
Filaković P; Koić O; Laufer D; Radanović-Grgurić L; Degmecić D; Pozgain I
Coll Antropol; 2007 Dec; 31(4):1105-9. PubMed ID: 18217467
[TBL] [Abstract][Full Text] [Related]
13. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
Guina J; Roy S; Gupta A; Langleben DD; Elman I
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
[TBL] [Abstract][Full Text] [Related]
14. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
[TBL] [Abstract][Full Text] [Related]
15. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
16. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.
Chiu CC; Chen KP; Liu HC; Lu ML
J Clin Psychopharmacol; 2006 Oct; 26(5):504-7. PubMed ID: 16974193
[TBL] [Abstract][Full Text] [Related]
17. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
[TBL] [Abstract][Full Text] [Related]
18. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
19. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
20. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration.
Ritchie CW; Harrigan S; Mastwyk M; Macfarlane S; Cheesman N; Ames D
Int J Geriatr Psychiatry; 2010 Apr; 25(4):411-8. PubMed ID: 19946860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
